U.S. Markets open in 7 mins

Henry Schein to Showcase New Dental Offerings at GNYDM

Zacks Equity Research

Henry Schein, Inc. HSIC announced that it will be exhibiting the new lineup of products and educational offerings at the 2019 Greater New York Dental Meeting (GNYDM), which is slated to start on Nov 29. The company’s suite of solutions, education, and social media activities, featuring pioneers in the dental industry, should enable oral healthcare professionals to explore new options revolutionizing digital dentistry.

The portfolio of digital equipment and technology solutions set to be displayed at the GNYDM includes its practice management, marketing, and patient engagement software solutions from Henry Schein One; a wide array of financial, business, and office design services and solutions from Henry Schein Financial Services, and Henry Schein ProRepair. The company will also be hosting a live event to demonstrate the optimization of Dentrix treatment plans and other workflow solutions designed to enhance productivity.

Products to be Demonstrated

At the meeting, Henry Schein will demonstrate the latest products and technology solutions such as 3Shape TRIOS Move, 3Shape TRIOS 3 Basic, the A-dec 500 chair, Convergent Dental Solea Dental Laser, and Dentsply Sirona CEREC Primescan. Henry Schein’s Exclusive Product Specialists will be presenting the new Clinician’s Choice Bluewave Laser, Reveal Clear Aligners, and other unique product offerings available from Clinician’s Choice, Sheer White, and Sprig Oral Health Technologies.

Recent Developments Within Dental Arm

Henry Schein’s strategy of expanding digital dentistry on a global basis is encouraging. It is busy promoting digital workflows for general dentistry and dental specialties. The company is currently focusing on offering a diversified portfolio and value-added services within the dental space.

Lately, it has been investing in acquisitions that should strengthen its international presence in the dental implant space.

In August, the company announced the acquisition of Cliniclands that offers dental consumables, implants, prosthetic, and orthodontic solutions and equipment to dentists in Sweden, Denmark, and Norway. In July 2019, Henry Schein announced its foray into the Italian dental practice management software market with the small but crucial acquisition of Elite Computer Italia. In June 2019, it acquired Hayes Handpiece franchise, a leading provider of dental handpiece products and services in the United States, Canada, and the United Kingdom.

Price Performance

In the past six months, the stock has rallied 3.4% against the industry’s 8.8% decline.

Zacks Rank and Stocks Worth a Look

Henry Schein currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Haemonetics Corporation HAE, NuVasive, Inc. NUVA and ResMed RMD. While Haemonetics carries a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Haemonetics has a projected long-term earnings growth rate of 13.5%.

NuVasive has an expected long-term earnings growth rate of 10.9%.

ResMed has a long-term earnings growth rate of 12.9%.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.

This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Haemonetics Corporation (HAE) : Free Stock Analysis Report
 
ResMed Inc. (RMD) : Free Stock Analysis Report
 
NuVasive, Inc. (NUVA) : Free Stock Analysis Report
 
Henry Schein, Inc. (HSIC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research